Kenta’s technology for the generation and selection of an advanced class of fully human monoclonal antibodies (MAbs) combines the advantages of classical hybridoma technology with a unique specific heteromyeloma fusion cell line.
Kenta`s patent portfolio currently consists of 3 patent families. The IP portfolio consists further of trademarks and domains.
•
It is Kenta's intention to expand its portfolio by further patent applications for the individual targets (antigens related to nosocomial infections) and technologies.
•
In addition Kenta will acquire and seek to acquire as needed or desired, exclusive license rights through others.
